Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ESP025
MIFTS: 43

Esophagus Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Esophagus Adenocarcinoma

About this section

MalaCards integrated aliases for Esophagus Adenocarcinoma:

Name: Esophagus Adenocarcinoma 12 15
Adenocarcinoma of Esophagus 45 74
Oesophageal Adenocarcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4914
MeSH 45 C562730
NCIt 51 C4025
UMLS 74 C0279628
Sources

Summaries for Esophagus Adenocarcinoma

About this section
Disease Ontology : 12 An esophageal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Esophagus Adenocarcinoma, also known as adenocarcinoma of esophagus, is related to adenocarcinoma and barrett esophagus. An important gene associated with Esophagus Adenocarcinoma is HNF1A-AS1 (HNF1A Antisense RNA 1), and among its related pathways/superpathways are Gastric cancer and Colorectal Cancer Metastasis. The drugs Levoleucovorin and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and bone, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Sources

Related Diseases for Esophagus Adenocarcinoma

About this section

Diseases related to Esophagus Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 144)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 30.0 ERBB2 HNF1A-AS1 PTGS2 SMAD4 TP53
2 barrett esophagus 29.9 CDX2 ERBB2 PTGS2 TP53
3 gastroesophageal reflux 29.8 CDX2 PTGS2 TP53
4 adenoma 29.6 PTGS2 SMAD4 TP53
5 squamous cell carcinoma 29.6 ERBB2 HNF1A-AS1 PTGS2 SMAD4 TP53
6 gastric adenocarcinoma 29.0 CDX2 ERBB2 PTGS2 SMAD4 TP53
7 esophageal cancer 28.7 CDX2 ERBB2 MIR21 PTGS2 SMAD4 TP53
8 lung cancer 28.1 AFAP1-AS1 ERBB2 HNF1A-AS1 MIR143 MIR145 MIR21
9 gastric cancer 27.3 AFAP1-AS1 CDX2 ERBB2 HNF1A-AS1 MIR143 MIR145
10 gastric papillary adenocarcinoma 10.4 ERBB2 TP53
11 pleomorphic adenoma carcinoma 10.4 ERBB2 TP53
12 non-proliferative fibrocystic change of the breast 10.4 ERBB2 TP53
13 uterine corpus serous adenocarcinoma 10.4 ERBB2 TP53
14 mutyh-associated polyposis 10.4 SMAD4 TP53
15 breast squamous cell carcinoma 10.4 ERBB2 TP53
16 uterine body mixed cancer 10.4 ERBB2 TP53
17 glioma susceptibility 1 10.4 ERBB2 TP53
18 microglandular adenosis 10.4 ERBB2 TP53
19 endocrine gland cancer 10.3 ERBB2 SMAD4 TP53
20 breast benign neoplasm 10.3 ERBB2 TP53
21 breast adenocarcinoma 10.3 ERBB2 SMAD4 TP53
22 thoracic benign neoplasm 10.2 ERBB2 TP53
23 nasal cavity adenocarcinoma 10.2 CDX2 TP53
24 uterine corpus cancer 10.2 ERBB2 TP53
25 vulva adenocarcinoma 10.2 CDX2 ERBB2
26 leukemia, chronic lymphocytic 2 10.2 MIR143 MIR145 TP53
27 biliary papillomatosis 10.2 CDX2 TP53
28 tongue squamous cell carcinoma 10.2 AFAP1-AS1 MIR21 TP53
29 hidradenocarcinoma 10.2 CDX2 ERBB2 TP53
30 endocervical adenocarcinoma 10.1 CDX2 TP53
31 protoplasmic astrocytoma 10.1 PTGS2 TP53
32 ovarian serous carcinoma 10.1 MIR143 MIR145 MIR21
33 recurrent respiratory papillomatosis 10.1 PTGS2 TP53
34 helicobacter pylori infection 10.1
35 fungal esophagitis 10.1 ATP12A ATP4A
36 diclofenac allergy 10.1 ATP12A ATP4A
37 gastroduodenal crohn's disease 10.1 ATP12A ATP4A
38 neonatal candidiasis 10.1 ATP12A ATP4A
39 squamous papillomatosis 10.1 ATP12A ATP4A
40 toxic megacolon 10.1 ATP12A ATP4A
41 aspiration pneumonitis 10.1 ATP12A ATP4A
42 gastrointestinal neuroendocrine benign tumor 10.1 ATP12A ATP4A
43 gastric antral vascular ectasia 10.1 ATP12A ATP4A
44 granulomatous gastritis 10.1 ATP12A ATP4A
45 esophageal candidiasis 10.1 ATP12A ATP4A
46 gastric neuroendocrine neoplasm 10.0 ATP12A ATP4A
47 acute laryngitis 10.0 ATP12A ATP4A
48 laryngitis 10.0 ATP12A ATP4A
49 duodenitis 10.0 ATP12A ATP4A
50 rumination disorder 10.0 ATP12A ATP4A

Graphical network of the top 20 diseases related to Esophagus Adenocarcinoma:



Diseases related to Esophagus Adenocarcinoma
Sources

Symptoms & Phenotypes for Esophagus Adenocarcinoma

About this section

MGI Mouse Phenotypes related to Esophagus Adenocarcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 ATP12A ATP4A CDX2 ERBB2 PTGS2 SMAD4
2 endocrine/exocrine gland MP:0005379 9.5 ATP4A CDO1 CDX2 ERBB2 PTGS2 SMAD4
3 neoplasm MP:0002006 9.1 ATP4A CDX2 ERBB2 PTGS2 SMAD4 TP53
Sources

Drugs & Therapeutics for Esophagus Adenocarcinoma

About this section

Drugs for Esophagus Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 191)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 68538-85-2
2
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 6006 143
3
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
4
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
5
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 61825-94-3 6857599 5310940 9887054 43805
6
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 7440-70-2 271
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
8 Liver Extracts Phase 4,Phase 2,Phase 1
9 Folate Phase 4,Phase 2,Phase 3,Phase 1
10 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
11 Vitamin B9 Phase 4,Phase 2,Phase 3,Phase 1
12 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
13 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
15 topoisomerase I inhibitors Phase 4,Phase 2,Phase 1
16 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
17 Antidotes Phase 4,Phase 2,Phase 3,Phase 1
18 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
19 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
21 Hormones Phase 4,Phase 3,Phase 2,Phase 1
22 Nutrients Phase 4,Phase 2,Phase 3,Phase 1
23 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1
24 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
25 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
26
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
27
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
28
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
29
Esomeprazole Approved, Investigational Phase 3 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
30
Cetuximab Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 205923-56-4 56842117 2333
31
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 154361-50-9 60953
32
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
33
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
34
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
35
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
36
Trioxsalen Approved Phase 3,Phase 2 3902-71-4 5585
37
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
38
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2 1177-87-3
39
Ranitidine Approved Phase 3 66357-59-3, 66357-35-5 3001055
40
Ondansetron Approved Phase 3 99614-02-5 4595
41
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
42
Ipilimumab Approved Phase 2, Phase 3 477202-00-9
43
nivolumab Approved Phase 2, Phase 3 946414-94-4
44
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1 180288-69-1 9903
45 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
47 Analgesics Phase 3,Phase 2,Phase 1
48 Analgesics, Non-Narcotic Phase 3,Phase 2,Phase 1
49 Proton Pump Inhibitors Phase 3
50 Antirheumatic Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 285)
# Name Status NCT ID Phase Drugs
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
3 Combination Chemotherapy in Treating Patients With Esophageal Cancer Unknown status NCT00041262 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil
4 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Unknown status NCT00357682 Phase 3 Esomeprazole;Esomeprazole;Aspirin
5 STRETTA ,Radio Frequency Ablation (RFA) v/s Sham Therapy for the Treatment of Refractory GERD Unknown status NCT02935881 Phase 3
6 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3 chemotherapy;cisplatin;fluorouracil
7 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3 cisplatin;fluorouracil
8 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3 capecitabine;cisplatin
9 Confocal Endomicroscopy for Barrett's Esophagus Completed NCT00487695 Phase 3
10 Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer Completed NCT00047112 Phase 3 cisplatin;fluorouracil
11 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00002631 Phase 3 chemotherapy;cisplatin;fluorouracil
12 Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00003118 Phase 3 cisplatin;fluorouracil
13 Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer Completed NCT00020787 Phase 3 cisplatin;fluorouracil
14 Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer Completed NCT00861094 Phase 2, Phase 3 cisplatin;5-FU;oxaliplatin;Folinic Acid
15 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3
16 Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery Completed NCT01107639 Phase 3 cisplatin;docetaxel
17 Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer Completed NCT00978549 Phase 3 docetaxel;steroid therapy
18 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Completed NCT00052910 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil;leucovorin calcium
19 Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus Recruiting NCT02509286 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
20 NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) Recruiting NCT01726452 Phase 3 Epirubicin;Cisplatin;5 Flourouracil/ Capecitabine;Paclitaxel;Carboplatin
21 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction Recruiting NCT01523015 Phase 2, Phase 3
22 A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Recruiting NCT03013010 Phase 3 Tegafur-Gimeracil-Oteracil Potassium;Oxaliplatin
23 Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Recruiting NCT02628665 Phase 3 photosensitizer(photofrin)
24 Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery Recruiting NCT03604991 Phase 2, Phase 3 Carboplatin;Paclitaxel
25 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Active, not recruiting NCT01196390 Phase 3 Carboplatin;Paclitaxel
26 Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer Not yet recruiting NCT03801876 Phase 3 Carboplatin;Paclitaxel
27 Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma Unknown status NCT00964080 Phase 1, Phase 2 MBP-426/Leucovorin/5-FU
28 The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma Unknown status NCT00674167 Phase 2 Docetaxel;Cisplatin;Capecitabine
29 Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia Unknown status NCT01362127 Phase 2 Chemotherapy
30 Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach Unknown status NCT00601705 Phase 2 cisplatin;epirubicin hydrochloride;fluorouracil;oxaliplatin
31 Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus Unknown status NCT00903136 Phase 1, Phase 2
32 Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus Unknown status NCT00003326 Phase 2 paclitaxel
33 Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer Unknown status NCT00006472 Phase 2 carboplatin;fluorouracil;paclitaxel
34 Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus Unknown status NCT00005607 Phase 2 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
35 Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer Unknown status NCT00004236 Phase 2 pegylated liposomal doxorubicin hydrochloride
36 Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery Unknown status NCT00005876 Phase 2 rubitecan
37 Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma Completed NCT00220103 Phase 2 epirubicin, capecitabine, cisplatin
38 Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma Completed NCT00583674 Phase 2 AMG 386 placebo;AMG 386 10mg/kg;AMG 386 3mg/kg;Cisplatin;Capecitabine;Cisplatin;Capecitabine;Cisplatin;Capecitabine
39 Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus Completed NCT00259987 Phase 2 Lapatinib (GW572016) oral tablets
40 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction Completed NCT00077545 Phase 2 triapine;cisplatin
41 A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects Completed NCT02096666 Phase 1, Phase 2 AMG 337
42 Phase II Study of Irinotecan and Panitumumab Completed NCT00836277 Phase 2 Panitumumab;Irinotecan
43 Irinotecan in Treating Patients With Esophageal or Stomach Cancer Completed NCT00003748 Phase 2 irinotecan hydrochloride
44 Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Completed NCT00591123 Phase 2 FOLFOX and Erlotinib
45 Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer Completed NCT00354679 Phase 2 cisplatin;irinotecan hydrochloride
46 Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction Completed NCT00891878 Phase 2 capecitabine;sunitinib malate
47 Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus Completed NCT00066716 Phase 2 carboplatin;celecoxib;paclitaxel
48 Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach Completed NCT00020761 Phase 2 irinotecan hydrochloride;paclitaxel
49 Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach Completed NCT00003237 Phase 2 cisplatin;paclitaxel
50 Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer Completed NCT00985192 Phase 2 everolimus

Search NIH Clinical Center for Esophagus Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma of esophagus

Sources

Genetic Tests for Esophagus Adenocarcinoma

About this section
Sources

Anatomical Context for Esophagus Adenocarcinoma

About this section

MalaCards organs/tissues related to Esophagus Adenocarcinoma:

42
Testes, Colon, Bone, Lymph Node
Sources

Publications for Esophagus Adenocarcinoma

About this section

Articles related to Esophagus Adenocarcinoma:

(show all 19)
# Title Authors Year
1
C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis. ( 27636117 )
2017
2
Preliminary evaluation for Bit1 as a potential biomarker for squamous cell carcinoma and adenocarcinoma of esophagus. ( 28488526 )
2017
3
The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma. ( 28184414 )
2017
4
Epigenetic regulation on the gene expression signature in esophagus adenocarcinoma. ( 28049580 )
2016
5
Four cases of adenocarcinoma of esophagus with co-existing hydatid cyst of liver which caused delayed management of carcinoma esophagus. ( 24869991 )
2015
6
In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. ( 24708360 )
2014
7
Esophagus adenocarcinoma in a young patient with celiac disease; Is celiac disease a predisposing factor for esophagus adenocarcinoma as well as squamous cell carcinoma? ( 26185881 )
2014
8
Research on the typical miRNA and target genes in squamous cell carcinoma and adenocarcinoma of esophagus cancer with DNA microarray. ( 24519530 )
2014
9
Increase of epidermal growth factor receptor expression in progression of GERD, Barrett, and adenocarcinoma of esophagus. ( 22875307 )
2013
10
Esophagogastric metaplasia relates to nodal metastases in adenocarcinoma of esophagus and cardia. ( 23434259 )
2013
11
Comparative evaluation of serum C-reactive protein (CRP) levels in the different histological subtypes of esophageal cancer (squamous cell carcinoma and adenocarcinoma of esophagus). ( 22467322 )
2012
12
Hedgehog signaling activation in the development of squamous cell carcinoma and adenocarcinoma of esophagus. ( 22509480 )
2012
13
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. ( 21166737 )
2010
14
Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. ( 17236199 )
2007
15
Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. ( 16985029 )
2006
16
WITHDRAWN: Expression of p53, p63, and p73 isoforms in squamous cell carcinoma and adenocarcinoma of esophagus☆,☆☆ ( 16126170 )
2005
17
Motor neuronopathy associated with adenocarcinoma of esophagus. ( 15129881 )
2004
18
Ultrasound-guided fine-needle aspiration diagnosis of adenocarcinoma of esophagus with signet-ring cell features arising in Barrett's esophagus: a case report. ( 9664184 )
1998
19
Meningeal carcinomatosis in patient with esophagus adenocarcinoma. ( 9105327 )
1997
Sources

Variations for Esophagus Adenocarcinoma

About this section
Sources

Expression for Esophagus Adenocarcinoma

About this section
Search GEO for disease gene expression data for Esophagus Adenocarcinoma.
Sources

Pathways for Esophagus Adenocarcinoma

About this section

Pathways related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Gastric cancer 38
Show member pathways
 12.29 CDX2 ERBB2 SMAD4 TP53
2
Colorectal Cancer Metastasis 65
11.65 PTGS2 SMAD4 TP53
3
MicroRNAs in cancer 38
11.64 ERBB2 MIR143 MIR145 MIR21 MIR215 PTGS2
4
DNA Damage Response (only ATM dependent) 1
11.39 ERBB2 SMAD4 TP53
5
Hepatitis C and Hepatocellular Carcinoma 1
10.84 PTGS2 SMAD4 TP53
Sources

GO Terms for Esophagus Adenocarcinoma

About this section

Biological processes related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.81 MIR21 PTGS2 SMAD4 TP53
2 positive regulation of protein kinase B signaling GO:0051897 9.71 ERBB2 MIR143 MIR21
3 negative regulation of angiogenesis GO:0016525 9.63 MIR143 MIR145 MIR21
4 regulation of ERK1 and ERK2 cascade GO:0070372 9.55 ERBB2 MIR145
5 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.52 MIR143 MIR21
6 regulation of smooth muscle contraction GO:0006940 9.49 MIR143 MIR145
7 cellular sodium ion homeostasis GO:0006883 9.48 ATP12A ATP4A
8 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.43 ATP12A ATP4A
9 cellular potassium ion homeostasis GO:0030007 9.4 ATP12A ATP4A
10 sodium ion export across plasma membrane GO:0036376 9.37 ATP12A ATP4A
11 angiotensin-activated signaling pathway GO:0038166 9.32 MIR143 MIR145
12 aorta smooth muscle tissue morphogenesis GO:0060414 9.26 MIR143 MIR145
13 regulation of phenotypic switching GO:1900239 9.16 MIR143 MIR145
14 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 8.96 MIR143 MIR145
15 negative regulation of cardiac muscle hypertrophy GO:0010614 8.8 MIR145 MIR21 SMAD4

Molecular functions related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen GO:0016702 9.16 CDO1 PTGS2
2 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
3 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A
Sources

Sources for Esophagus Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....